1190927-76-4 Usage
General Description
7-Bromo-3-methyl-[1,2,4]triazolo[4,3-a]pyridine is a chemical compound with the molecular formula C6H5BrN4. It is a heterocyclic compound containing a pyridine ring fused to a triazole ring, with a bromine atom and a methyl group attached to the triazole ring. 7-Bromo-3-methyl-[1,2,4]triazolo[4,3-a]pyridine has potential applications in the pharmaceutical industry, specifically in the development of new drugs and therapeutic agents. It may also be used as a building block in organic synthesis and chemical research. Due to its unique structure and properties, 7-Bromo-3-methyl-[1,2,4]triazolo[4,3-a]pyridine is of interest to chemists and researchers studying heterocyclic compounds and their biological activities.
Check Digit Verification of cas no
The CAS Registry Mumber 1190927-76-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,9,0,9,2 and 7 respectively; the second part has 2 digits, 7 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1190927-76:
(9*1)+(8*1)+(7*9)+(6*0)+(5*9)+(4*2)+(3*7)+(2*7)+(1*6)=174
174 % 10 = 4
So 1190927-76-4 is a valid CAS Registry Number.
1190927-76-4Relevant articles and documents
INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION
-
Paragraph 1972, (2020/03/01)
Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.
CYCLIC INHIBITORS OF 11 β-HYDROXYSTEROID DEHYDROGENASE 1
-
Page/Page column 71, (2010/08/18)
This invention relates to novel compounds of the Formula Formulas (I), (Ia1-20), (Ib1-20), (Ic1-20), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell.
